Symbiomix Therapeutics' Acquisition

Symbiomix Therapeutics was acquired by Lupin on October 11, 2017.

Symbiomix is a held biopharmaceutical company with a focus on women's health. The company's lead product, SYM-1219, is a new anti-infective drug being studied as the first oral one-and-done treatment …

Articles about Symbiomix Therapeutics' Acquisition: